Cargando…

Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb

Parkinson’s disease (PD) is a neurodegenerative disease characterized by progressive motor symptoms and alpha-synuclein (αsyn) aggregation in the nervous system. For unclear reasons, PD patients with certain GBA mutations (GBA-PD) have a more aggressive clinical progression. Two testable hypotheses...

Descripción completa

Detalles Bibliográficos
Autores principales: Walton, Sara, Fenyi, Alexis, Tittle, Tyler, Sidransky, Ellen, Pal, Gian, Choi, Solji, Melki, Ronald, Killinger, Bryan A., Kordower, Jeffrey H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473741/
https://www.ncbi.nlm.nih.gov/pubmed/37662402
http://dx.doi.org/10.1101/2023.08.24.554646
_version_ 1785100327951794176
author Walton, Sara
Fenyi, Alexis
Tittle, Tyler
Sidransky, Ellen
Pal, Gian
Choi, Solji
Melki, Ronald
Killinger, Bryan A.
Kordower, Jeffrey H.
author_facet Walton, Sara
Fenyi, Alexis
Tittle, Tyler
Sidransky, Ellen
Pal, Gian
Choi, Solji
Melki, Ronald
Killinger, Bryan A.
Kordower, Jeffrey H.
author_sort Walton, Sara
collection PubMed
description Parkinson’s disease (PD) is a neurodegenerative disease characterized by progressive motor symptoms and alpha-synuclein (αsyn) aggregation in the nervous system. For unclear reasons, PD patients with certain GBA mutations (GBA-PD) have a more aggressive clinical progression. Two testable hypotheses that can potentially account for this phenomenon are that GBA1 mutations promote αsyn spread or drive the generation of highly pathogenic αsyn polymorphs (i.e., strains). We tested these hypotheses by treating homozygous GBA1 D409V knockin (KI) mice with human α-syn-preformed fibrils (PFFs) and treating wild-type mice (WT) with several αsyn-PFF polymorphs amplified from brain autopsy samples collected from patients with idiopathic PD and GBA-PD patients with either homozygous or heterozygous GBA1 mutations. Robust phosphorylated-αsyn (PSER129) positive pathology was observed at the injection site (i.e., the olfactory bulb granular layer) and throughout the brain six months following PFF injection. The PFF seeding efficiency and degree of spread were similar regardless of the mouse genotype or PFF polymorphs. We found that PFFs amplified from the human brain, regardless of patient genotype, were generally more effective seeders than wholly synthetic PFFs (i.e., non-amplified); however, PFF concentration differed between these two studies, and this might also account for the observed differences. To investigate whether the molecular composition of pathology differed between different seeding conditions, we permed Biotinylation by Antibody Recognition on PSER129 (BAR-PSER129). We found that for BAR-PSER129, the endogenous PSER129 pool dominated identified interactions, and thus, very few potential interactions were explicitly identified for seeded pathology. However, we found Dctn2 interaction was shared across all PFF conditions, and Nckap1 and Ap3b2 were unique to PFFs amplified from GBA-PD brains of heterozygous mutation carriers. In conclusion, both the genotype and αsyn strain had little effect on overall seeding efficacy and global PSER129-interactions.
format Online
Article
Text
id pubmed-10473741
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-104737412023-09-02 Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb Walton, Sara Fenyi, Alexis Tittle, Tyler Sidransky, Ellen Pal, Gian Choi, Solji Melki, Ronald Killinger, Bryan A. Kordower, Jeffrey H. bioRxiv Article Parkinson’s disease (PD) is a neurodegenerative disease characterized by progressive motor symptoms and alpha-synuclein (αsyn) aggregation in the nervous system. For unclear reasons, PD patients with certain GBA mutations (GBA-PD) have a more aggressive clinical progression. Two testable hypotheses that can potentially account for this phenomenon are that GBA1 mutations promote αsyn spread or drive the generation of highly pathogenic αsyn polymorphs (i.e., strains). We tested these hypotheses by treating homozygous GBA1 D409V knockin (KI) mice with human α-syn-preformed fibrils (PFFs) and treating wild-type mice (WT) with several αsyn-PFF polymorphs amplified from brain autopsy samples collected from patients with idiopathic PD and GBA-PD patients with either homozygous or heterozygous GBA1 mutations. Robust phosphorylated-αsyn (PSER129) positive pathology was observed at the injection site (i.e., the olfactory bulb granular layer) and throughout the brain six months following PFF injection. The PFF seeding efficiency and degree of spread were similar regardless of the mouse genotype or PFF polymorphs. We found that PFFs amplified from the human brain, regardless of patient genotype, were generally more effective seeders than wholly synthetic PFFs (i.e., non-amplified); however, PFF concentration differed between these two studies, and this might also account for the observed differences. To investigate whether the molecular composition of pathology differed between different seeding conditions, we permed Biotinylation by Antibody Recognition on PSER129 (BAR-PSER129). We found that for BAR-PSER129, the endogenous PSER129 pool dominated identified interactions, and thus, very few potential interactions were explicitly identified for seeded pathology. However, we found Dctn2 interaction was shared across all PFF conditions, and Nckap1 and Ap3b2 were unique to PFFs amplified from GBA-PD brains of heterozygous mutation carriers. In conclusion, both the genotype and αsyn strain had little effect on overall seeding efficacy and global PSER129-interactions. Cold Spring Harbor Laboratory 2023-08-25 /pmc/articles/PMC10473741/ /pubmed/37662402 http://dx.doi.org/10.1101/2023.08.24.554646 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Walton, Sara
Fenyi, Alexis
Tittle, Tyler
Sidransky, Ellen
Pal, Gian
Choi, Solji
Melki, Ronald
Killinger, Bryan A.
Kordower, Jeffrey H.
Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb
title Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb
title_full Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb
title_fullStr Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb
title_full_unstemmed Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb
title_short Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb
title_sort neither alpha-synuclein-preformed fibrils derived from patients with gba1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473741/
https://www.ncbi.nlm.nih.gov/pubmed/37662402
http://dx.doi.org/10.1101/2023.08.24.554646
work_keys_str_mv AT waltonsara neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb
AT fenyialexis neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb
AT tittletyler neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb
AT sidranskyellen neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb
AT palgian neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb
AT choisolji neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb
AT melkironald neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb
AT killingerbryana neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb
AT kordowerjeffreyh neitheralphasynucleinpreformedfibrilsderivedfrompatientswithgba1mutationsnorthehostmurinegenotypesignificantlyinfluenceseedingefficacyinthemouseolfactorybulb